Combangio, Inc.

8 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Feb 2040

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Nov 23, 2026
The maintenance fee for Processes for Making and Using a Mesenchymal Stem Cell Derived Secretome (US 11,654,160) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
1 fee due Aug 6, 2027
The maintenance fee for Cellular Fibronectin Compositions (US 11,891,428) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
1 fee due Sep 5, 2027
The maintenance fee for Methods for Treating an Ocular Condition with Cellular Fibronectin Compositions (US 11,919,942) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Patent	Title	Status	Expires	Confidence
US 10,758,571	Processes for Making and Using a Mesenchymal Stem Cell Derived Secretome In force Ends no later than Feb 7, 2040 · Medium confidence	In force	Ends no later than Feb 7, 2040	Medium confidence
US 10,881,693	Processes for Making and Using a Mesenchymal Stem Cell Derived Secretome In force Ends no later than Feb 7, 2040 · Medium confidence	In force	Ends no later than Feb 7, 2040	Medium confidence
US 11,129,853	Processes for Making and Using a Mesenchymal Stem Cell Derived Secretome In force Ends no later than Feb 7, 2040 · Medium confidence	In force	Ends no later than Feb 7, 2040	Medium confidence
US 11,654,160	Processes for Making and Using a Mesenchymal Stem Cell Derived Secretome In force Term ends Feb 7, 2040 · Medium confidence	In force	Term ends Feb 7, 2040	Medium confidence
US 12,186,430	Lyophilized Mesenchymal Stem Cell Derived Secretome and Uses Thereof In force Term ends Feb 7, 2040 · Medium confidence	In force	Term ends Feb 7, 2040	Medium confidence
US 11,891,428	Cellular Fibronectin Compositions In force Term ends Jul 1, 2042 · High confidence	In force	Term ends Jul 1, 2042	High confidence
US 11,919,942	Methods for Treating an Ocular Condition with Cellular Fibronectin Compositions In force Term ends Jul 1, 2042 · High confidence	In force	Term ends Jul 1, 2042	High confidence
US 12,187,784	Processes for Making a Cellular Fibronectin Composition In force Term ends Jul 1, 2042 · High confidence	In force	Term ends Jul 1, 2042	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending

List them